
$Absci(ABSI.US) | BTIG ๐ข๐ง๐ข๐ญ๐ข๐๐ญ๐๐ฌ ๐๐จ๐ฏ๐๐ซ๐๐ ๐ on ๐๐๐ฌ๐๐ข with a ๐๐ฎ๐ฒ rating, sets ๐๐ ๐๐ญ $๐
Analyst initiates coverage on the biotech's generative AI platform, projecting peak sales of $2.2B for its lead drug candidate ABS-201.The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

